Overview

Heart and Estrogen-Progestin Replacement Study (HERS)

Status:
Completed
Trial end date:
2001-07-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine whether hormone replacement therapy in post menopausal women with coronary artery disease prevents future heart attacks or death from coronary heart disease.
Phase:
Phase 3
Details
Lead Sponsor:
University of California, San Francisco
Collaborator:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Estrogens
Estrogens, Conjugated (USP)
Medroxyprogesterone
Medroxyprogesterone Acetate
Progestins